- Home
- SKYE
as 07-08-2024 4:00pm EST
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 294.2M | IPO Year: | N/A |
| Target Price: | $19.67 | AVG Volume (30 days): | 476.6K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $19.41 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Skye Bioscience Inc. Common Stock (SKYE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| 5AM Partners VII, LLC | SKYE | 10% Owner | Mar 13 '24 | Buy | $10.00 | 450,000 | $4,500,000.00 | 8,393,520 | SEC Form 4 |
| 5AM Partners VII, LLC | SKYE | 10% Owner | Jan 31 '24 | Buy | $2.31 | 5,206,074 | $12,026,030.94 | 7,943,520 | SEC Form 4 |
Latest Skye Bioscience Inc. Common Stock News
SKYE Breaking Stock News: Dive into SKYE Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
GlobeNewswire
8 days ago
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
GlobeNewswire
14 days ago
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
PR Newswire
a month ago
NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities
GlobeNewswire
a month ago
Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*
Business Wire
a month ago
Form 8.3 - International Distribution Services plc
Business Wire
a month ago
Form 8.3 - Darktrace plc
Reuters
a month ago
US Supreme Court rejects Kroger challenge to Grubhub trademark win
Share on Social Networks:
Disclaimer
The information presented on this page, "SKYE Skye Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.